Relationship between Pain and Injection Site during Intravitreal Injection.
10.3341/jkos.2016.57.6.930
- Author:
Kyeong Do JEONG
1
;
Jung Hoon KIM
;
Jae Suk KIM
;
Je Hyung HWANG
Author Information
1. Department of Ophthalmology, Inje University Sanggye Paik Hospital, Seoul, Korea. violentviolet15@daum.net
- Publication Type:Clinical Trial ; Original Article
- Keywords:
Intravitreal injection;
Pain measurement;
Visual analogue scale
- MeSH:
Bevacizumab;
Central Serous Chorioretinopathy;
Dexamethasone;
Diabetic Retinopathy;
Humans;
Intravitreal Injections*;
Macular Degeneration;
Pain Measurement;
Prospective Studies;
Ranibizumab;
Retinal Vein Occlusion
- From:Journal of the Korean Ophthalmological Society
2016;57(6):930-934
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Using a visual analogue scale, patients pain was compared according to injection site during intravitreal injection. METHODS: A prospective, clinical trial was conducted on 171 eyes of patients experiencing age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, or central serous chorioretinopathy. After determining the anatomic quadrant of the injection site, patients were randomized to receive intravitreal bevacizumab, aflibercept, ranibizumab, or dexamethasone injection. Fifteen minutes after the injection, patients completed a survey about pain using a visual analogue scale from 0 (no pain) to 10 (unbearable pain). RESULTS: According to the visual analogue scale, pain score was 3.20 at the superotemporal site, 3.03 at the superonasal site, and 2.35 at the inferonasal site. Pain was lowest when injected in an inferotemporal site (p = 0.012). CONCLUSIONS: Intravitreal injection at an inferotemporal site can help reduce patient pain.
